GFH276 clinical trials
Also written GFH276.
How each study uses GFH276 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the GFH276 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- GFH276
- 3
Studies by the year they started
3 studies that test it; most in 2026 (2)
| Year | Studies |
|---|---|
| 2025 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Often tested with
Tested in the same studies.
Bevacizumab (1) · Pemetrexed (1) · Cisplatin (1) · Carboplatin (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test GFH276.
- Sep 2027A Single-Arm, Open-Label, Multicenter Phase I/II Clinical Study of GFH276 in Patients With RAS-Mutant Advanced Solid TumorsPhase 1/2 · Genfleet Therapeutics (Shanghai) Inc.
Studies
Open first, then newest update. How each study uses GFH276 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- A Phase Ib/II Study of GFH276 in Combination With Chemotherapy (± Bevacizumab) or Cetuximab in Patients With RAS-mutant Metastatic Colorectal CancerNot yet recruitingPhase 1/2Genfleet Therapeutics (Shanghai) Inc.NCT07915921Written as GFH276
- This is a Multicenter, Open-label, Phase I/II Study to Explore the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Efficacy of GFH276 in Patients With Advanced NSCLC Harboring a RAS Mutation.Not yet recruitingPhase 1/2Genfleet Therapeutics (Shanghai) Inc.NCT07846358Written as GFH276
- A Single-Arm, Open-Label, Multicenter Phase I/II Clinical Study of GFH276 in Patients With RAS-Mutant Advanced Solid TumorsNot yet recruitingPhase 1/2Genfleet Therapeutics (Shanghai) Inc.NCT07198321Written as GFH276
Given beside what is tested · 2 — GFH276 is usual care or a partner of the new treatment
- A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS MutationRecruitingPhase 1/2Genfleet Therapeutics (Shanghai) Inc.NCT07678593Written as GFH276
- A Phase II Study of GFH375 Combined With GFS202A or GFH276 Versus GFH375 in Patients With Previously Treated Locally Advanced Unresectable or Metastatic Pancreatic Cancer Harboring KRAS G12D MutationRecruitingPhase 2Genfleet Therapeutics (Shanghai) Inc.NCT07784374Written as GFH276